High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer.

"Conflict-of-interest disclosure: A.J.S. (spouse is an employee of Bristol Myers Squibb). R.N.P. is an employee of C2i Genomics. S.F.E. is an employee of Tempus Labs. W.X. has received research support from Stemline Therapeutics. M.F.B. has received consulting fees from Eli Lilly and AstraZeneca. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Bakx, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics, and Isoplexis; has received research support from 10.13039/100006483AbbVie, 10.13039/100025208Constellation, Ajax, Zentalis, and Prelude; has received research support from and consulted for 10.13039/100006436Celgene and 10.13039/100004337Roche; and has consulted for Syndax, Incyte, Janssen, Astellas, MorphoSys, and Novartis, and received honoraria from AstraZeneca, Novartis, Gilead and Novartis. S.M. has financial interests in a patent application relating to software described in this article (CEDARS: Clinical Event Detection and Recording System) and is principal owner of Daboia Consulting LLC. The remaining authors declare no competing financial interests."

"This work was supported by grants from the 10.13039/100008884Edward P. Evans Foundation (A.J.S., X.W., and R.L.L.), the 10.13039/100000002National Institutes of Health/10.13039/100000054National Cancer Institute P30-CA008748 (R.L.L.), K08-CA267058 (W.X.), T32-CA009207 (J.J.), and 10.13039/100017050Cycle for Survival (P.S.V., W.X., and R.L.L.)."